---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-008879"
form_type: "8-K"
ticker: "IBO"
cik: "0001834105"
company_name: "IMPACT BIOMEDICAL INC."
filed_at: "2026-03-04T23:59:59+00:00"
generated_at: "2026-05-15T21:47:42.050518+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Impact BioMedical amends merger deal with Dr Ashleys; extends deadline to July 1, 2026

## Summary
- Amendment adds 53,000 and 75,000 PubCo ordinary shares to be issued to DSS, Inc. at closing.
- Total Company Share Consideration set at 169,560,000 PubCo shares (94.20% of post-closing outstanding).
- Termination date extended from March 31, 2026 to July 1, 2026, with mutual extension option.
- Impact must seek board approval to co-sign loan agreements requested by PubCo or Dr Ashleys before effective time.
- Supporting stockholders now hold 92,980,843 Impact shares (88.87% fully diluted); holdings of DSS, Inc. and DSS BioHealth updated.

## SEC filing metadata
- accession: 0001493152-26-008879
- form_type: 8-K
- ticker: IBO
- cik: 0001834105
- company_name: IMPACT BIOMEDICAL INC.
- filed_at: 2026-03-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1834105/000149315226008879/0001493152-26-008879-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1834105/000149315226008879/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-008879
- JSON: https://secwatch.observer/filing/0001493152-26-008879.json
- Plain text: https://secwatch.observer/filing/0001493152-26-008879.txt

## Key facts
- Material Agreements
  IMPACT BIOMEDICAL INC. amended Amendment No. 1 to the Merger and Share Exchange Agreement with Dr Ashleys Limited, Dr Ashleys Nevada Sub, Inc., Dr Ashleys Bio Labs Limited, Kanans Visvanats (effective 2026-02-27).
  - Action: amendment
  - Agreement: merger
  - Counterparty: Dr Ashleys Limited, Dr Ashleys Nevada Sub, Inc., Dr Ashleys Bio Labs Limited, Kanans Visvanats
  - Effective: 2026-02-27
  source text: On February 27, 2026, the parties entered into Amendment No. 1 to the Merger and Share Exchange Agreement (the “Amendment to the Original Merger and Share Exchange Agreement” and, together with the Original Merger and Share Exchange Agreement, the “Merger and Share Exchange Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1834105/000149315226008879/0001493152-26-008879-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.